Cited by 690Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

The DOI matches its Crossref record; 23 of the 28 references it cites were found in a registry or an index.

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Open access

Tie, Jeanne, Cohen, Joshua D., Wang, Yuxuan, Christie, Michael, Simons, Koen, Lee, Margaret, Wong, Rachel, Kosmider, Suzanne, Ananda, Sumitra, McKendrick, Joseph, Lee, Belinda, Cho, Jin Hee, Faragher, Ian, Jones, Ian T., Ptak, Janine, Schaeffer, Mary J., Silliman, Natalie, Dobbyn, Lisa, Li, Lu, Tomasetti, Cristian, Papadopoulos, Nicholas, Kinzler, Kenneth W., Vogelstein, Bert, Gibbs, Peter·2019·JAMA Oncology

DOI 10.1001/jamaoncol.2019.3616PMC PMC6802034

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm diagnosed within the last 3 years were excluded. Median duration of follow-up was 28.9 months (range, 11.6-46.4 months). Physicians were blinded to ctDNA results. Data were analyzed from December 10, 2018, through June 23, 2019. Exposures: Serial plasma samples were collected after surgery and after chemotherapy. Somatic mutations in individual patients' tumors were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. Personalized assays were designed to quantify ctDNA. Main Outcomes and Measures: Detection of ctDNA and recurrence-free interval (RFI). Results: After 4 exclusions, 96 eligible patients were eligible; median patient age was 64 years (range, 26-82 years); 49 (51%) were men. At least 1 somatic mutation was identified in the tumor tissue of all 96 evaluable patients. Circulating tumor DNA was detectable in 20 of 96 (21%) postsurgical samples and was associated with inferior recurrence-free survival (hazard ratio [HR], 3.8; 95% CI, 2.4-21.0; P < .001). Circulating tumor DNA was detectable in 15 of 88 (17%) postchemotherapy samples. The estimated 3-year RFI was 30% when ctDNA was detectable after chemotherapy and 77% when ctDNA was undetectable (HR, 6.8; 95% CI, 11.0-157.0; P < .001). Postsurgical ctDNA status remained independently associated with RFI after adjusting for known clinicopathologic risk factors (HR, 7.5; 95% CI, 3.5-16.1; P < .001). Conclusions and Relevance: Results suggest that ctDNA analysis after surgery is a promising prognostic marker in stage III colon cancer. Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant treatment. This high-risk population presents a unique opportunity to explore additional therapeutic approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.3616

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citation
Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citation
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citation
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,105

Show all 28 references

Research works printed but not linked: 1

Song, 2008, A semiparametric approach for the covariate specific ROC curve with survival outcome., Stat Sin, 947

Sorted by citations

Items 401–500 of 690

Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches
Sanjeevaiah, A. R., Park, H., Fangman, B. D., & Porembka, M. R. (2020) · Cancers · doi:10.3390/cancers12030592 · Cited by 6
Postoperative CEA and Other Non-traditional Risk Factors for Colon Cancer Recurrence: Findings from Swedish Population-Based Data
Kwaan, M. R. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08151-8 · Cited by 6
Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer
Zhao, Z., Cai, S., & Wang, Z. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0283 · Cited by 6
Potential value of detection of minimal residual disease in colorectal cancer following radical resection
Pu, W., Chen, F., Tang, Y., Qu, Y., Han, Y., Zha, J., Jin, J., & Kong, F. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.04.07 · Cited by 5
The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer
Liu, M., Mu, T., Gu, J., Xu, M., & Chen, S. (2025) · Cancer Reports · doi:10.1002/cnr2.70167 · Cited by 5
High-Performance Silicon Nanowire Array Biosensor for Combined Detection of Colorectal Cancer Biomarkers
Zeng, J., Liu, M., Chen, X., Yi, J., Liu, W., Qu, X., Liu, C., Viriri, S., Yang, G., Yang, X., et al. (2025) · Micromachines · doi:10.3390/mi16101089 · Cited by 5
Circulating Tumor DNA-Based Assessment of Minimal Residual Disease in Colorectal Cancer: Prognostic and Predictive Implications
Özlük, A. A., Colley, W., Arik, Z. B., Köstek, O., Sunkari, A., Malla, M., & Akce, M. (2026) · Cancers · doi:10.3390/cancers18050754 · Cited by 5
The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review
Jiang, T., Lu, C. L., Shen, Y., Meng, W., Chen, H. R., & Wang, Z. (2026) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2026.102411 · Cited by 5
Liquid biopsy can cure early colorectal cancer recurrence – Case Report
Baraniskin, A., Baba, H. A., Theegarten, D., Mika, T., Schroers, R., & Klein‐Scory, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1141833 · Cited by 5
Response prediction by mutation- or methylation-specific detection of ctDNA dynamics in pretreated metastatic colorectal cancer
Doleschal, B., Kirchweger, P., Schwendinger, S., Kupferthaler, A., Burghofer, J., Webersinke, G., Jukic, E., Wundsam, H., Biebl, M., Petzer, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231200462 · Cited by 5
Association of the immediate perioperative dynamics of circulating DNA levels and neutrophil extracellular traps formation in cancer patients
Kudriavtsev, A., Pastor, B., Mirandola, A., Pisareva, E., Gricourt, Y., Capdevila, X., Thierry, A. R., & Cuvillon, P. (2024) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbae008 · Cited by 5
Early Detection, Precision Treatment, Recurrence Monitoring: Liquid Biopsy Transforms Colorectal Cancer Therapy
Raval, H., & Bhattacharya, S. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096295070240318075023 · Cited by 5
Development and validation of a circulating tumor DNA-based optimization-prediction model for short-term postoperative recurrence of endometrial cancer
Liu, Y., Lu, X., Guo, H., Bao, C., Zhang, J., & Jin, Y.-N. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i18.3385 · Cited by 5
Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer
van de Weerd, S., Torang, A., van den Berg, I., Lammers, V., van den Bergh, S., Brouwer, N. P. M., Nagtegaal, I. D., Koopman, M., Vink, G. R., van der Baan, F. H., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35120 · Cited by 6
Impact of Sensitive Circulating Tumor DNA Monitoring on CT Scan Intervals During Postoperative Colorectal Cancer Surveillance
Sasaki, T., Iwaya, T., Yaegashi, M., Idogawa, M., Hiraki, H., Abé, M., Koizumi, Y., Sasaki, N., Yashima‐Abo, A., Fujisawa, R., et al. (2025) · Annals of Surgery Open · doi:10.1097/as9.0000000000000549 · Cited by 5
Microfluidic approaches for liquid biopsy in glioblastoma: Insights into diagnostic and follow‐up strategies
Bayona, C., Ranđelović, T., Olaizola‐Rodrigo, C., & Ochoa, I. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70032 · Cited by 5
Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
Tanaka, K., Yoshida, Y., Yamada, T., Hayashi, T., Shimaoka, H., Yoshimura, F., Kajitani, R., Munechika, T., Matsumoto, Y., Nagano, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92795-8 · Cited by 5
Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies
Zhu, M., Taylor, W. R., Mahoney, D. W., Then, S. S., Berger, C. K., Burger, K. N., Gonser, A. M., Doering, K. A., Xie, H., Foote, P. H., et al. (2023) · Cancers · doi:10.3390/cancers15245778 · Cited by 5
Circulating DNA in Rectal Cancer to Unravel the Prognostic Potential for Radiation Oncologist
Fiorica, F., Mandarà, M., Giuliani, J., Tebano, U., Franceschetto, A., Gabbani, M., Rampello, E., Condarelli, G., Napoli, G., Luca, N., et al. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001148 · Cited by 5
Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
Malik, Y. G., Lyckander, L. G., Lindstrøm, J. C., Vinge-Holmquist, O., Sheikh, A. E., Schultz, J., & Ignjatović, D. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03381-w · Cited by 5
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions
Lam, R. C. T., Johnson, D., Lam, G., Li, M. L. Y., Wong, J. W. L., Lam, W. K., Chan, K. C. A., & Ma, B. B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.970242 · Cited by 5
Construction and Validation of a Novel Prognosis Model in Colon Cancer Based on Cuproptosis-Related Long Non-Coding RNAs
Liang, G.-Z., Wen, X., Song, Y., Zhang, Z., Chen, J., Chen, Y., Pan, W., He, X., Hu, T., & Xian, Z. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041528 · Cited by 5
Rs11479 in Thymidine Phosphorylase Associated with Prognosis of Patients with Colorectal Cancer Who Received Capecitabine-Based Adjuvant Chemotherapy
Jia, X., Zhang, T., Sun, J., Lin, H., Bai, T., Qiao, Y., Li, Y., Li, G., Li, G., Peng, X., et al. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s397382 · Cited by 5
Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2021) · Der Chirurg · doi:10.1007/s00104-021-01486-7 · Cited by 5
ctDNAtools: An R package to work with sequencing data of circulating tumor DNAPreprint
Alkodsi, A., Meriranta, L., Pasanen, A., & Leppä, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.27.912790 · Cited by 5
Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study)
Hashimoto, T., Tsukada, Y., Ito, M., Kanato, K., Mizusawa, J., Fukuda, H., Tsukamoto, S., Takashima, A., & Kanemitsu, Y. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-073217 · Cited by 4
Tumor microbiome analysis provides prognostic value for patients with stage III colorectal cancer
Kim, J. H., Yu, J., Kim, D.-K., Lee, S., Lee, S. H., Ahn, B. K., Kim, T. I., & Park, S. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1212812 · Cited by 4
Predictive biomarkers in colorectal adenocarcinoma – a Brazilian perspective on current and future practices
Campos, A. H. J. F. M., Auresco, L. C., Marins, L. V., Divino, P. H. D. A., Sabbaga, J., & Hoff, P. M. (2024) · Surgical and Experimental Pathology · doi:10.1186/s42047-024-00163-3 · Cited by 4
Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer
Yanes, R. B., Saridogan, T., Gorantla, V. C., Overacre-Delgoffe, A. E., Hsieh, R. W., Celebrezze, J. P., Magge, T., Singh, M., Saeed, A., Zureikat, A. H., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251317094 · Cited by 4
The Influence of Mucinous Histology on the Prognosis of Stage II and III Colorectal Cancers
Aydın, İ. C., Torun, M., Sönmez, M. R., Ademoğlu, S., Sunar, A. O., Uzun, O., Gülmez, Ş., Polat, E., & Duman, M. (2025) · Medicina · doi:10.3390/medicina61030456 · Cited by 4
Multi-omics evaluation of peritoneal fluid in gastroesophageal cancer (OMEGCA): protocol for a prospective multicentre cohort study to detect occult peritoneal metastases in patients undergoing curative-intent treatment
Liu, D. S., Allan, Z., Tie, J., Hall, K., Lee, M., Wong, D. J., Wong, S. Q., Tebbutt, N. C., Watson, D. I., Trochsler, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318615 · Cited by 4
Self-citation
Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer
Zhu, H., Jia, Y., Pang, F., Xing, X., Li, S., Shan, F., & Li, Z. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17397-4 · Cited by 4
Added value of tumor–stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy
Franken, I. A., Heilijgers, F., Bakker, M.-C. E., Alarcon, C. R., van der Baan, F. H., Lemmens, M., Diemen, P. D.-V., Sausen, M., Meijer, G. A., Koopman, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.105935 · Cited by 4
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation
Baden, J. F., Lin, C.-H. J., Anfora, A., Beer, J. P., Bisselou, K. S., Bungo, J., Corner, A. S., Danek, T., Dickey, J. S., Godsey, J. H., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00267 · Cited by 5
Re-evaluating post-polypectomy surveillance: The role of non-invasive modalities in colorectal cancer prevention
McFerran, E., McKay, D., Loughrey, M. B., Lawler, M., & McSorley, S. T. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102092 · Cited by 4
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 4
MiSelect R System: the validation of a new detection system of CTCs and their correlation with prognosis in non-metastatic CRC patients
Lin, C., Yang, C., Hung, T.-C., Wang, C., Wei, S.-W., Schiro, P. G., Tseng, J.-Y., Lin, C., & Jiang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-31346-9 · Cited by 4
Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy
Kong, W., Chen, T., & Li, Y. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3346-5_9 · Cited by 4
Utility of Circulating Tumor DNA in Appendiceal Tumors
Bhutiani, N., Helmink, B. A., Zeineddine, M. A. A., Uppal, A., Shen, J. P., Spickard, E. A., & White, M. G. (2023) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-023-05825-3 · Cited by 4
Explorative cost-effectiveness analysis of colorectal cancer recurrence detection with next-generation sequencing liquid biopsy in Spain, France, and Germany
Schramm, W., Hollenbenders, Y., & Kurscheidt, M. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241248246 · Cited by 4
Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification
Fu, R., Xiong, Y., Cai, M., Li, F., Chen, R., Wu, Y.-L. L. C., & Zhong, W. (2024) · Frontiers of Medicine · doi:10.1007/s11684-024-1060-z · Cited by 4
Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies
To, Y. H., Lee, B., Wong, H., Gibbs, P., & Tie, J. (2020) · Visceral Medicine · doi:10.1159/000509657 · Cited by 4
Self-citation
Liquid profiling for cancer patient stratification in precision medicine – current status and challenges for successful implementation in standard care
Haselmann, V., Hedtke, M., & Neumaier, M. (2022) · Journal of Laboratory Medicine · doi:10.1515/labmed-2022-0066 · Cited by 4
Circulating tumour DNA in colorectal cancer management
Cohen, R., Platell, C. F. E., McCoy, M. J., Meehan, K. L., & Fuller, K. A. (2023) · British journal of surgery · doi:10.1093/bjs/znad126 · Cited by 5
Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
Makarem, M., García-Pardo, M., & Leighl, N. B. (2021) · Cancers · doi:10.3390/cancers13215299 · Cited by 4
Trial Protocol of a Phase II Study of mFOLFOXIRI after Metastasectomy in Patients with Oligometastatic Colorectal Cancer (FANTASTIC Study)
Kataoka, K., Takeshi, Y., Yamazaki, K., Mori, K. P., Matsuhashi, N., Shiozawa, M., Iwai, T., Goto, M., Yasui, M., Takii, Y., et al. (2024) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2024-025 · Cited by 6
Prediction of Therapeutic Response and Prognosis in Ovarian Cancer Patients With Plasma Circulating Biomarkers
Cheng, H., Yuan, G., Liang, L., Wang, T., Zhu, J., Yang, H., Zhou, Z., Wang, P., Song, Q., Jiao, Y., et al. (2025) · Cancer Innovation · doi:10.1002/cai2.70014 · Cited by 3
CtDNA-guided de-escalation of adjuvant chemotherapy in stage III colon cancer: early model-based evaluation of cost-effectiveness
Wang, H., Kramer, A., Greuter, M. J. E., Alarcon, C. R., Lissenberg-Witte, B. I., Meijer, G. A., Kok, N. F. M., van den Broek, D. A., Vink, G. R., Roodhart, J. M. L., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251384238 · Cited by 3
Perioperative Systemic Stress Phenotypes Predict Immune Recovery Failure, Molecular Residual Disease, and Long‐Term Outcomes After Colorectal Cancer Surgery: A Prospective Cohort Study
Pan, S., & Wang, G. (2026) · World Journal of Surgery · doi:10.1002/wjs.70360 · Cited by 3
Liquid Biopsy in Advanced Colorectal Cancer: Clinical Applications of Different Analytes
Delcuratolo, M. D., Modrego-Sánchez, A., Bungaro, M., Antón-Pascual, B., Terán, S., Dipace, V., Novello, S., García‐Carbonero, R., Passiglia, F., & Graválos-Castro, C. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4030013 · Cited by 3
Utilização de DNA Tumoral Circulante na Análise de Prognóstico de Pacientes com Tumores Malignos Sólidos do Trato Gastrintestinal: Revisão Sistemática
Abreu, G., de Brito, M. A., & Ramos, A. P. D. S. (2025) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2024v70n4.4873 · Cited by 3
Jagged-1 Expression Level Is Correlated With Recurrence of Stage III Colorectal Cancer in Patients Receiving Adjuvant Chemotherapy
Kim, H.-B., LEE, S.-B., Kim, S., Lee, H.-J., & Park, S.-G. (2021) · Anticancer Research · doi:10.21873/anticanres.15278 · Cited by 3
SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study
You, D., Zhang, S., Yan, S., Ding, Y., Li, C., Cheng, X., Wu, L., Wang, W., Zhang, T., Li, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939982 · Cited by 3
The prognostic value of circulating in blood tumor DNA as a marker of minimal residual disease in stage I–III colorectal cancer
Максимовна, П. Е., Fedyanin, M. Y., Boyarskikh, U. A., Андреевич, К. А., Анатольевна, М. Е., Khrapov, E. A., Oskorobin, I. P., Shamovskaya, D. V., Алиев, В. А., Mammadli, Z., et al. (2022) · Advances in molecular oncology · doi:10.17650/2313-805x-2022-9-2-32-42 · Cited by 3
The T-CEA score: a useful prognostic indicator based on postoperative CEA and pathological T4 levels for patients with stage II–III colorectal cancer
Sonoda, H., Yamada, T., Matsuda, A., Yokoyama, Y., Ohta, R., Shinji, S., Yonaga, K., Iwai, T., Takeda, K., Ueda, K., et al. (2023) · Surgery Today · doi:10.1007/s00595-023-02644-6 · Cited by 3
Risk factors for the postoperative recurrence of ulcerative colitis-associated colorectal cancer
Horio, Y., Uchino, M., Igeta, M., Nagano, K., Kusunoki, K., Kuwahara, R., Kimura, K., Kataoka, K., Beppu, N., Ikeda, M., et al. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04410-z · Cited by 3
Therapeutische Relevanz molekularer Marker beim kolorektalen Karzinom
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2020) · Der Onkologe · doi:10.1007/s00761-020-00777-8 · Cited by 3
Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
Naidoo, M., Piercey, O., & Tie, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01137-4 · Cited by 3
Self-citation
Prognostic value of elastic lamina staining in patients with stage III colon cancer
Bi, F., Li, X., Zhang, Y., Wang, Z., Dong, Q., Zhang, J., & Sun, D. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02865-y · Cited by 3
Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review
To, Y. H., Gibbs, P., Tie, J., IJzerman, M. J., & Degeling, K. (2023) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-023-00422-2 · Cited by 3
Self-citation
Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation
Zhong, L., Yin, R., & Song, L. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s397827 · Cited by 3
Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28–29, October 2022
Gill, S., Ahmed, S., Anderson, B. J., Berry, S. R., Lim, H. J., Phang, P. T., Sharma, A. M., Vasconcelos, J. P. S., Gill, K. K., Iqbal, M., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090579 · Cited by 3
Identification of Genomic Signatures for Colorectal Cancer Survival Using Exploratory Data Mining
Hummel, J. J., Liu, D., Tallon, E. M., Snyder, J., Warren, W. C., Shyu, C., Mitchem, J. B., & Cortese, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063220 · Cited by 3
SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.
Han, X., Wang, Z., Zhang, L., Shen, Y., Tan, Q., Sun, Y., Wang, J., Qian, X., Yang, H., & Shi, Y. (2021) · PubMed Central · Cited by 3
New Insights into Adjuvant Therapy for Localized Colon Cancer
Gonzalez, N. S., Ros, J., Illescas, D. G., Argota, I. B., Ballabrera, F. S., & Elez, M. E. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.006 · Cited by 5
Prognostic significance of additional histologic features for subclassification of pathological T3 colon cancer
Macchi, L., Bao, Q. R., Albertoni, L., Fassan, M., Chiminazzo, V., Scarpa, M., Spolverato, G., & Pucciarelli, S. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02192-y · Cited by 3
Mind the target: circulating tumour DNA in gastrointestinal malignancies
Fontana, E., & Ignatova, E. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000846 · Cited by 3
Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure
Lucchesi, N., Ally, J. M., & Reilley, M. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007434 · Cited by 3
Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers
Landon, B. V., Huang, J., Evangelopoulou, E. G., Anagnostou, V., & Canzoniero, J. V. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.12.002 · Cited by 2
RUNX1 promotes colorectal cancer progression by activating SERPINE1 transcription
Yang, Y., Deng, S., Yin, Q., Zhang, T., Liu, T., Wu, D., & Xu, Y. X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151732 · Cited by 2
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS
Massaro, G., Venturini, J., Rossini, D., Vannini, A., Brugia, M., Lavacchi, D., Conticello, C., Valle, I., Ravizza, D., Pillozzi, S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104746 · Cited by 2
The 3PM transformation potential of minimal residual disease in solid tumor management: a bibliometric analysis and review
Chen, Y., Li, X., Zhao, S., Zhang, Y., Wang, H., Na, F., Guan, Q., Li, Z., Li, H., & Zhao, M. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00413-8 · Cited by 2
Ultrasound-targeted microbubble destruction mediated upregulation of CNN1 induces ferroptosis in colorectal cancer cells by regulating p53-related SLC7A11 expression
Wang, L., Wang, W., Wu, S., & Shi, Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152207 · Cited by 2
Circulating Tumor DNA in Primary and Secondary Liver Cancers: A Comprehensive Review
Hong, H., Wehrle, C. J., Karakaya, O. F., Tocci, N. X., Kumar, P., Sun, K., Jiao, C., Satish, S., Panconesi, R., Esfeh, J. M., et al. (2025) · Frontiers in Bioscience-Scholar · doi:10.31083/fbs26972 · Cited by 2
A 14‐Gene Panel for Predicting Colorectal Cancer Recurrence Using Circulating Tumor DNA in Different Testing Conditions
Hisamatsu, Y., Ando, K., Kudo, K., Nakanishi, R., Kawazoe, T., Zaitsu, Y., Kusumoto, T., Hata, T., Kagawa, Y., Yoshizumi, T., et al. (2025) · Cancer Science · doi:10.1111/cas.70114 · Cited by 2
Prognostic Value of Circulating Tumor DNA for Recurrence Risk in Stage III Colorectal Cancer: A Systematic Review and Meta-Analysis
Aliyeva, T., Siddiqui, H., Natche, J., Al-Wraikat, Y. A., Hossain, F. M., & El-Amri, I. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.10.004 · Cited by 2
Microfluidic biosensors and devices for brain tumor diagnosis and monitoring
Allela, O. Q. B., Alkhazali, W. H., Arora, V., Prahlad, P., Mohanty, B., Dhyani, A., Uppal, S., Aliev, M. A., Sameer, H. N., Yaseen, A., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120796 · Cited by 2
Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients
Franken, I. A., Ketelaars, S. L. C., Alarcon, C. R., Diemen, P. D., Spaapen, T. O. M., Heilijgers, F., Guimaraes, M. D. S., van Nassau, S. C. M. W., Schraa, S. J., Mesker, W. E., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116262 · Cited by 2
Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review
Romeo, M., Nardo, F. D., Napolitano, C., Vaia, P., Basile, C., Senese, G., Coppola, A., Iodice, P., Olivieri, S., Federico, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103579 · Cited by 2
Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter study
Yuan, X., Jin, R., Wei, Y., He, Y., Weng, L., Li, Z., Wang, J. A., Li, X., Xu, J., Bai, J., et al. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0023 · Cited by 2
Self-citation
Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer
Cohen, R., Beasley, A. B., McCoy, M. J., Platell, C. F. E., Meehan, K. L., Gray, E. S., & Fuller, K. A. (2023) · ANZ Journal of Surgery · doi:10.1111/ans.18385 · Cited by 2
Role of Circulating Tumor DNA in Colorectal Cancer
Li, H., Lu, S., Zhou, Z., Zhu, X., & Shao, Y. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3346-5_15 · Cited by 2
Diagnostic discovery
Wolfe, A. R., Wang, K., Perlow, H. K., Ritter, A. R., Facer, B. D., & Prasad, R. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88423-5.00048-0 · Cited by 2
Cutting-Edge Technological Developments in the Diagnosis and Treatment of Malignant Gastric Neoplasm
Goel, M., & Gupta, V. (2025) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-031-80189-1_16 · Cited by 2
Research trends and prospects of Circulating tumor DNA associated with colorectal cancer: a bibliometric analysis
Xia, S., Liu, L., Zhou, Y., Zhu, Y., Dai, Q., & Peng, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03394-2 · Cited by 2
Molecular genetic testing in colon cancer: clinical aspects
Martianov, A. S., Kuligina, E. S., Romanko, A. A., & Имянитов, Е. Н. (2022) · Almanac of Clinical Medicine · doi:10.18786/072-0505-2022-50-002 · Cited by 2
Identification of circulating tumor DNA as a biomarker for diagnosis and response to therapies in cancer patients
Hsieh, R. W., Symonds, L. K., Siu, J. J., & Cohen, S. A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.006 · Cited by 2
Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer
Lee, Y., Park, S.-Y., Lee, G. K., Lim, H.-J., Choi, Y., Kim, J., & Han, J. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-273 · Cited by 2
Advances in Cell-Free DNA
Barrie, E. S., & Ferreira‐Gonzalez, A. (2022) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2022.08.002 · Cited by 2
Is the Patient Cured?
BURKE, H. B., & Kopetz, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3612 · Cited by 2
Comment on “Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer”
Zhang, Q., Xu, B., & Xue, Z. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003856 · Cited by 2
Liver transplantation for non-resectable colorectal liver metastases
Aziz, H., Sharif, S., Gribovskaja‐Rupp, I., & Hemming, A. W. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-270 · Cited by 2
Circulating tumour DNA for detection of minimal residual disease in head and neck squamous cell carcinoma: A new hope
Lam, W. K., Kang, G., & Wong, W. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.693 · Cited by 2
Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
Akagündüz, B., Güven, D. C., Özer, M., Ökten, I. N., Atağ, E., Ünek, İ. T., Tatlı, A. M., & Karaoğlu, A. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.08.016 · Cited by 1
The prognostic role of post-operative cfDNA after resection of colorectal liver metastases: A systematic review and meta-analysis
Vail, E., Boland, P. M., Beninato, T., Eskander, M. F., Grandhi, M. S., In, H., Kennedy, T. J., Langan, R. C., Maggi, J. C., Moore, D. F., et al. (2024) · Surgical Oncology Insight · doi:10.1016/j.soi.2024.100013 · Cited by 1
A Concise Overview of Circulating Tumor DNA Detection for Solid Tumors
Goold, E. A., Raps, E., & McMurtry, V. (2024) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2024.06.005 · Cited by 1
Local excision in rectal cancer: When and for whom?
Atıcı, S. D., Canda, A. E., & Terzi, M. C. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i9.106146 · Cited by 1
Outcomes and survival trends following pelvic exenteration for locally advanced and recurrent rectal cancer: a 20-Year analysis from a tertiary cancer center in India
Ray, M. D., Kumar, A., & Kapoor, R. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04053-0 · Cited by 1
Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study
Fukumoto, Y., Kataoka, K., Muroi, Y., Koba, M., Ito, K., Rao, Z., Imada, A., Jihyung, S., Horio, Y., Kuwahara, R., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02943-7 · Cited by 1
Evaluation of Circulating miR‐155, miR‐221, miR‐34a, and miR‐143 for Monitoring Tumor Clearance After Surgery in Colorectal Cancer
Ham-Karim, H. A. (2025) · Journal of Surgical Oncology · doi:10.1002/jso.70166 · Cited by 1

Authors: Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
Affiliations: The University of Melbourne (AU)
Johns Hopkins University (US)
The Royal Melbourne Hospital (AU)
Walter and Eliza Hall Institute of Medical Research (AU)
Western Health (AU)
Eastern Health (AU)
Division of Biostatistics & Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland
Corresponding author: Tie, Jeanne
ORCID: Tie, Jeanne
Cohen, Joshua D.
Wang, Yuxuan
Christie, Michael
Simons, Koen
Wong, Rachel
Kosmider, Suzanne
Lee, Belinda
Cho, Jin Hee
Faragher, Ian
Jones, Ian T.
Ptak, Janine
Silliman, Natalie
Dobbyn, Lisa
Tomasetti, Cristian
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2019-12-01
Volume: 5
Issue: 12
Pages: 1710
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2019.3616
PMC: PMC6802034
OpenAlex: W2980567593
Cited by: 668
References: 28
Citations by year: 2026: 76 · 2025: 91 · 2024: 104 · 2023: 124 · 2022: 107 · 2021: 102 · 2020: 57 · 2019: 6
FWCI: 21.84
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (P50CA062924)
National Institute of General Medical Sciences (T32GM136577)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords: circulating tumor DNA, stage III colon cancer, adjuvant chemotherapy, recurrence risk, minimal residual disease, recurrence-free interval, somatic mutations, liquid biopsy, predictive biomarkers, treatment response monitoring, recurrent colorectal cancer, recurrence-free survival, prognostic factors
MeSH terms: Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Australia, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Biomarkers, Tumor, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Disease-Free Survival, Precision Medicine, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks